bentiromide (chymex) Report issue

Small molecule Imaging Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Bentiromide (Chymex) is a diagnostic agent that was approved for the diagnosis of pancreatic exocrine insufficiency. It is given by mouth as a noninvasive test. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the United States or Canada.   NCATS

Chemistry

  • SMILES: OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C3=CC=CC=C3)C=C1
  • InChIKey: SPPTWHFVYKCNNK-FQEVSTJZSA-N
  • Mol. Mass: 404.4153
  • ALogP: 3.07
  • ChEMBL Molecule:
    bentiromide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

bentiromide | bentiromido | bentiromidum | benzoyl-tyrosyl-paba | btpaba | btpaba pft | chymex | e-2663 | n-benzoyl-l-tyrosyl-paba | n-benzoyl-l-tyrosyl-p-aminobenzoic acid | paba-peptide | pft

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Exocrine Pancreatic Insufficiency (approved 1983)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue